Tyra Biosciences宣布其2期研究Beach301中首位儿童患者接受Dabogratinib (Tyra-300)给药,该研究针对儿童软骨发育不全症。
Tyra Biosciences宣布其2期研究Beach301中首位儿童患者接受Dabogratinib (Tyra-300)给药,该研究针对儿童软骨发育不全症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.